We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Nanoparticles Deliver Small RNAs to Treat Pancreatic Cancer

By LabMedica International staff writers
Posted on 06 Feb 2018
A team of Israeli cancer researchers used novel supramolecular nanocarriers to deliver a potent combination of microRNA and siRNA to attach and destroy pancreatic ductal adenocarcinoma (PDAC) tumors in a mouse model.
 
MicroRNAs (miRNAs) are a small noncoding family of 19- to 25-nucleotide RNAs that regulate gene expression by targeting messenger RNAs (mRNAs) in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. More...
Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.
 
Short interfering RNAs (siRNAs) have a well-defined structure: a short (usually 21 base pairs) double-stranded RNA (dsRNA) with phosphorylated 5' ends and hydroxylated 3' ends with two overhanging nucleotides. These small RNAs can bind to other specific messenger RNA (mRNA) molecules and either increase or decrease their activity, for example by preventing an mRNA from producing a protein. RNA interference has an important role in defending cells against parasitic nucleotide sequences – viruses and transposons – but also in directing development as well as gene expression in general.
 
Investigators at Tel Aviv University (Israel) conjugated in parallel ethylenediamine and alkylamine moieties to form positively charged amphiphilic nanocarriers. These cationic nanocarriers were designed to utilize electrostatic-based interactions to form polyplexes with the negatively charged oligonucleotide cargo. The nanocarriers would facilitate oligonucleotide delivery by improving their stability in the bloodstream and enabling accumulation of the polyplexes at the tumor site due to enhanced permeability and the retention effect.
 
Based findings gleaned from The Cancer Genome Atlas (TCGA), the investigators used two negatively charged small RNAs: miR-34a for miRNA replacement therapy and PLK1 (polo like kinase 1)-siRNA for oncogene silencing in a PDAC mouse model.
 
They reported in the January 2, 2018, online edition of the journal Nature Communications that systemic administration of the RNA polyplexes to PDAC-bearing mice showed no toxicity and accumulated at the tumor, resulting in an enhanced antitumor effect due to inhibition of the MYC oncogene, a common target of both miR-34a and PLK1.
 
"Though 75% of pancreatic cancer patients die within 12 months of diagnosis, about 7% survive more than five years," said senior author Dr. Ronit Satchi-Fainaro, professor of physiology and pharmacology at Tel Aviv University. "We thought that if we could understand how some people live several years with this most aggressive disease, we might be able to develop a new therapeutic strategy. This treatment takes into account the entire genomic pattern, and shows that affecting a single gene is not enough for the treatment of pancreatic cancer or any cancer type in general."
 

New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The advanced test enables early, definitive detection of respiratory infections and pneumonia in critically ill patients (Photo courtesy of Shutterstock)

Rapid Test Detects Early Signs of Pneumonia in Critically Ill Hospitalized Patients

Hospital-acquired infections (HAIs) remain a significant source of life-threatening illness in intensive care, demanding fast and accurate diagnosis to ensure effective treatment. Hospital-acquired pneumonia... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.